Arcturus Therapeutics Holdings Inc. ARCT
Set alert
11.03 USD -1.12 -9.22%
At close · Oct 30
10.51 -0.52 -4.67%
After hours · Oct 30, 6:12 PM ET
10.58 Day range 11.93
5.50 52-week range 17.96
- YTD
- +79.93%
- 1 year
- +14.54%
- Open
- 11.81
- Prev close
- 12.15
- Mkt cap
- 313.51M
- Vol
- 1.85M
- Avg vol
- 992.01K
- EPS
- -3.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.58
- High
- 11.93
- Forward P/E
- -7.41
- Beta
- 2.64
- Short ratio
- 9.41
- Inst. own
- 90.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.22
- 200-d avg
- 24.44
- 1y target
- 79.47
5Y chart
Events in this range
- Aug 7, 2023Earnings: -1.98; estimate 0.09; surprise -2300%
- Nov 14, 2023Earnings: -0.61; estimate -1.79; surprise 65.92%
- Mar 7, 2024Earnings: -0.32; estimate -1.69; surprise 81.07%
- May 8, 2024Earnings: -1; estimate -1.17; surprise 14.53%
- Aug 5, 2024Earnings: -0.64; estimate -1.85; surprise 65.41%
- Aug 6, 2024Rating: Cantor Fitzgerald · — → Overweight
- Aug 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 12, 2024Rating: Leerink Partners · — → Outperform
- Nov 7, 2024Earnings: -0.26; estimate -0.7; surprise 62.86%
- Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 16, 2024Rating: Cantor Fitzgerald · Overweight → Overweight
- Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (96)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | May 27, 2024 | 2 years ago |
| SMA: Bullish | May 20, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| RSI: Overbought | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Jun 26, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 26, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 19, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 29, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 27, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| SMA: Bullish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Dec 12, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 447.75M
- Enterprise value
- 211.56M
- Trailing P/E
- 0.00
- Forward P/E
- -7.41
- PEG ratio
- 0.00
- Price / sales
- 2.79
- Price / book
- 1.71
- EPS (TTM)
- -2.33
- Beta
- 2.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -39.05%
- Revenue (TTM)
- 160.40M
- Revenue growth
- -7.70%
- Free cash flow
- -40.26M
- Total cash
- 237.18M
- Total debt
- 29.42M
- Return on equity
- -23.12%
- Shares outstanding
- 27.09M
- Short % of float
- 25.29%
- 50-day average
- 18.22
- 200-day average
- 24.44
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 79.47 +620.5% upside
Now 11.03
- Target (low)
- 44.00
- Target (mean)
- 79.47
- Target (high)
- 140.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.22333.
Financials — quick view
ARCT Revenue — quarterly 2.96M
ARCT Net income — quarterly -23.79M
ARCT EPS — quarterly -0.84
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.70 | -0.26 | +0.44 | +62.86% |
| Aug 5, 2024 | Jun 1, 2024 | -1.85 | -0.64 | +1.21 | +65.41% |
| May 8, 2024 | Mar 1, 2024 | -1.17 | -1.00 | +0.17 | +14.53% |
| Mar 7, 2024 | Dec 1, 2023 | -1.69 | -0.32 | +1.37 | +81.07% |
| Nov 14, 2023 | Sep 1, 2023 | -1.79 | -0.61 | +1.18 | +65.92% |
| Aug 7, 2023 | Jun 1, 2023 | 0.09 | -1.98 | -2.07 | -2,300.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | Leerink Partners | init | — | Outperform |
| Aug 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2024 | Cantor Fitzgerald | reit | — | Overweight |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcturusrx.com
News
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
- Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
- Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
- 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
- Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
- Why Is Arcturus Therapeutics Stock Gaining Thursday?
- Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
- Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on ARCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARLOW JAMES F. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 13,131 |
| CHIVUKULA PADMANABH | Chief Operating Officer | Sale | Oct 14, 2024 | 435,334 |
| FARRELL PETER CRAIG | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 98,696 |
| HOLMES EDWARD W. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 3,131 |
| KUMMERFELD KEITH C | Officer | Sale | Jul 13, 2023 | 950 |
| MARANTZ JING L. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 3,131 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 17.33% | 4,694,060 | 77.59M | Sep 29, 2024 |
| Blackrock Inc. | 10.90% | 2,952,013 | 48.80M | Sep 29, 2024 |
| Nikko Asset Management Americas, Inc. | 8.55% | 2,315,294 | 38.27M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 8.40% | 2,275,715 | 37.62M | Sep 29, 2024 |
| ARK Investment Management, LLC | 7.76% | 2,101,038 | 34.73M | Sep 29, 2024 |
| Vanguard Group Inc | 5.82% | 1,576,926 | 26.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 8.99% | 2,435,880 | 40.27M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 8.11% | 2,198,020 | 36.33M | Jul 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 7.53% | 2,038,675 | 33.70M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.77% | 749,644 | 12.39M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.67% | 723,640 | 11.96M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.19% | 593,781 | 9.82M | Oct 30, 2024 |